Tesla Kicks Off Magnificent 7 Earnings This Week After Its Stock Kicked Into High Gear
7 minutes ago
Halfway though 2025, Tesla stock looked like a big-time laggard.
The EV maker’s shares were down more than 20% through the first six months of the year—a stretch that was rough for just about everyone, though by the end of it the S&P 500 and Magnificent Seven group of tech shares had moved back into the green even as Tesla lagged. Then the third quarter happened: Tesla (TSLA) was the best-performing stock in the group of Big Tech elites, and here we are—with the shares now up some 10% since the start of 2025.
Where to next? Investors, at least for now, have signaled that they’re willing to look at the longer-term picture. Non-car-sales things—including optimism about robotaxis and robots, as well as a new pay proposal for Elon Musk and a big stock purchase by the CEO—were tailwinds. Several Wall Street analysts whose price targets hadn’t kept up finally got with it.
Shares of Tesla are in positive territory for the year after brushing off early 2025 pressure.
Ina Fassbender / AFP via Getty Images
“The Tesla story going forward is around the AI transformation being led by the autonomous and robotics initiatives,” Wedbush’s bullish analysts wrote in a note published Sunday.
There will, however, undoubtedly still be plenty of attention on its third-quarter earnings, due Wednesday afternoon.
Deliveries are already in hand, with the company turning in better than expected quarterly numbers, though an update to Tesla’s car lineup will likely mean renewed attention on signs about car demand. (Analysts have dutifully issued estimates: Visible Alpha’s means for revenue and net income are $26.6 billion and $1.5 billion, respectively.)
Read the full article here.
Moderna Leads S&P 500 Monday After Flu Vaccine Data
1 hr 10 min ago
Moderna (MRNA) shares were up roughly 7% to pace the S&P 500 Monday, a day after the pharma firm announced data for two influenza vaccine candidates at the IDWeek 2025 conference in Atlanta.
The Cambridge, Mass.-based company said that mRNA-1010, an mRNA-based flu vaccine, “is safe and efficacious” in adults 50 years or older. It added that a Phase 1/2 clinical study of mRNA-1018, a candidate to prevent H5N1 pandemic flu in healthy adults at least 18 years old demonstrated that across all dose levels, it was “well-tolerated with no safety concerns identified, and demonstrated rapid and persistent immune response.”
Despite today’s advance, Moderna shares have lost roughly a third of their value this year.
TradingView
Apple’s iPhone 17 Sales ‘Far Outpace’ Prior Lineup in US and China, Report Shows
1 hr 50 min ago
Apple shares climbed Monday following a report suggesting strong demand for the company’s new iPhone 17 series in the U.S. and China, which account for the bulk of the company’s phone sales.
Apple’s (AAPL) iPhone 17 outsold the iPhone 16 by 14% during the first 10 days of availability in the U.S. and China, according to a report from tech product research firm Counterpoint Research.
Shares of Apple climbed close to 3% in recent trading following the news to lead gains on the Dow Jones Industrial Average.
Counterpoint Research pointed to the iPhone 17 base model’s “great value” for its popularity.
David Paul Morris / Bloomberg via Getty Images
Counterpoint found the base model of the iPhone 17 was a big driver of sales in China, while the premium iPhone 17 Max saw strong demand in the U.S.
Counterpoint Senior Analyst Mengmeng Zhang pointed to the iPhone 17 base model’s “great value” for its performance, with “a better chip, improved display, higher base storage, selfie camera upgrade—all for the same price as last year’s iPhone 16.” Sales of the iPhone 17 base model in China were nearly double those of the 16 over a comparable period.
Meanwhile, the iPhone 17 Pro Max saw sales surge in the U.S., as Counterpoint said those who purchased Apple phones during the COVID-19 pandemic moved to upgrade and large carriers enticed buyers with higher subsidies.
Amazon Web Services Outage Causes Widespread Disruptions—What You Need to Know
2 hr 42 min ago
Companies that use Amazon Web Services are recovering after a problem with the cloud service disrupted operations at a wide range of companies Monday.
Some of the firms affected included trading platform Coinbase Global (COIN), and Snap’s (SNAP) social media site Snapchat, along with major airlines like Delta Air Lines (DAL) and United Airlines (UAL).
Amazon (AMZN) confirmed the glitch at 3:51 a.m. ET, and by 6:35 a.m. ET, said the issue had been “fully mitigated,” with most AWS Service operations back to normal. However, it added that it continued to work on some lingering disruptions.
Cesc Maymo / Getty Images
As of 8:40 a.m. ET, website problem reporting company Downdetector reported nearly 2,000 reports of outages possibly linked to AWS.2
The news sent Amazon shares tumbling in premarket trading, but shares rose close to 1% slightly after the open. They’ve lost about 2% of their value in 2025, compared to a 14% gain for the S&P 500.
USA Rare Earths Stock Pops as William Blair Initiates Coverage at ‘Outperform’
3 hr 6 min ago
Analysts from William Blair see plenty of upside for USA Rare Earths (USAR) shares.
The analysts initiated coverage of the stock and four others in the sector with an “outperform” rating, writing in a note to clients that “while many rare earth stocks have hit the cover off the ball in recent weeks, we believe there is still material future upside.”
William Blair noted that the Trump administration recently announced investments in MP Materials (MP), Lithium Americas (LAC), and Trilogy Metals (TMQ), and said that it believes “significant new financial backing and direct government stakes in rare earth companies could provide a second meaningful leg up for several rare earth stocks.”
USA Rare Earths shares, which entered Monday up more than 140% this year, surged 7% at the open.
TradingView
Trump Aims To Cure High Medicine Prices, But Experts See Serious Side Effects To His Moves
3 hr 59 min ago
The Trump administration has issued a flurry of orders aimed at lowering pharmaceutical prices, but experts are leery that the actions will achieve that goal.
The latest move in Trump’s ongoing campaign to reduce drug prices came late last month when the White House announced a deal between the government and Pfizer (PFE), the multinational company that makes COVID-19 vaccines, Viagra, and other widely used products.
Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House on Sept. 30, 2025.
Francis Chung / Politico/Bloomberg via Getty Images
Under the deal, which could serve as a model for agreements with other major manufacturers, the company will sell its products to Medicaid at prices on par with those offered to other developed countries. In addition, the company will offer medications directly to consumers at a discount on Trumprx.gov, a website scheduled to launch in 2026. In return, the company will be exempt from the punishing 100% tariffs Trump is threatening to impose on pharmaceutical imports.
The deal appears to address a longstanding complaint from Trump and U.S. consumer advocacy groups: the sticker prices for many drugs are significantly higher in the U.S. than in Europe. In some cases, drugs that cost thousands of dollars in the U.S. are available for low cost or for free to Europeans. For example, in 2021, a single injection of the arthritis drug Humira cost American patients $3,000, when a generic version was available in Germany for $10, according to reports.
Read the full article here.
Americans Are Already Holiday Shopping. Will They Find the Deals They Hope For?
5 hours ago
Americans aren’t expected to slash their holiday budgets this year. But they may spend more time hunting for bargains—and find smaller ones than they hoped.
Consumers are expected to approach the year-end shopping season with the same thrifty ethos they’ve adopted for much of 2025 as they look to deal with tariff-fueled price increases, analysts told Investopedia. Keen-to-save shoppers have already started surveying deals well ahead of “Black Friday,” surveys show, but many are holding off on buying.
Consumers may, on average, spend slightly less on the holidays this year, the NRF says.
Jeenah Moon / Bloomberg via Getty Images
New National Retail Federation research shows what others have already spotted: Americans plan to shop resale markets, hunt for deals and cut back on some purchases. On average, Americans plan to spend about 1.3% less on gifts, food, decorations and other seasonal items this November and December than a year earlier, the NRF said.
“It’s certainly going to be a weirder holiday season, at least form a consumer and brand perspective,” said Andrew Waber, who studies U.S. transactions on Amazon for PMG, a marketing and digital services company. “Purchase behavior may be a little different than what you expect.”
Read the full article here.
Stock Futures Tick Higher to Begin Week
5 hr 37 min ago
Futures tied to the Dow Jones Industrial Average ticked up 0.1%.
TradingView
S&P 500 futures rose 0.2%.
TradingView
Nasdaq 100 futures were 0.3% higher.
TradingView